Stockreport

Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Tango Therapeutics, Inc.  (TNGX) 
PDF – Positive TNG462 clinical activity across multiple tumor types in the phase 1/2 clinical trial, program moving into full development with multiple combination studies – [Read more]